DIVISLAB - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.1
| Stock Code | DIVISLAB | Market Cap | 1,58,427 Cr. | Current Price | 5,972 ₹ | High / Low | 7,078 ₹ |
| Stock P/E | 61.6 | Book Value | 578 ₹ | Dividend Yield | 0.50 % | ROCE | 20.6 % |
| ROE | 15.6 % | Face Value | 2.00 ₹ | DMA 50 | 6,253 ₹ | DMA 200 | 6,233 ₹ |
| Chg in FII Hold | 0.69 % | Chg in DII Hold | -0.50 % | PAT Qtr | 653 Cr. | PAT Prev Qtr | 696 Cr. |
| RSI | 35.7 | MACD | -45.6 | Volume | 1,27,058 | Avg Vol 1Wk | 1,97,835 |
| Low price | 4,942 ₹ | High price | 7,078 ₹ | PEG Ratio | -6.69 | Debt to equity | 0.01 |
| 52w Index | 48.3 % | Qtr Profit Var | 9.88 % | EPS | 94.8 ₹ | Industry PE | 27.2 |
📊 Divi’s Laboratories (DIVISLAB) has strong fundamentals with ROCE (20.6%) and ROE (15.6%), but trades at a very high P/E (61.6) compared to industry average (27.2). Technical indicators are weak (RSI 35.7, MACD -45.6, price below 50 & 200 DMA). Despite solid earnings and debt-free balance sheet, current bearish momentum makes it a cautious swing trade candidate.
💡 Optimal Entry Price: Around ₹5,900–6,000, near support levels.
📈 Exit Strategy (if already holding): Consider exiting near ₹6,250–6,350 if recovery occurs, or cut losses if price falls below ₹5,900 decisively.
Positive
- Strong ROCE (20.6%) and ROE (15.6%) indicate efficient capital use.
- Debt-to-equity ratio of 0.01 shows virtually debt-free balance sheet.
- EPS of ₹94.8 reflects solid earnings base.
- Quarterly PAT of ₹653 Cr. remains strong despite slight decline.
- Large market cap (₹1,58,427 Cr.) ensures liquidity and stability.
Limitation
- High P/E (61.6) compared to industry average (27.2), suggesting overvaluation.
- PEG ratio (-6.69) indicates poor growth-adjusted valuation.
- Price trading below both 50 DMA (6,253) and 200 DMA (6,233), confirming bearish trend.
- Quarterly PAT declined from ₹696 Cr. to ₹653 Cr., showing earnings pressure.
Company Negative News
- DII holdings decreased (-0.50%), reflecting reduced domestic institutional confidence.
- Technical weakness with RSI near oversold zone and MACD negative.
Company Positive News
- FII holdings increased (+0.69%), showing foreign investor confidence.
- Quarterly profit variation (+9.88%) indicates resilience despite decline in absolute PAT.
Industry
- Industry P/E at 27.2 is much lower than Divi’s Laboratories’, suggesting the stock trades at a steep premium.
- Pharmaceutical sector remains defensive and growth-oriented, supported by global demand for APIs and formulations.
Conclusion
⚖️ Divi’s Laboratories is fundamentally strong but technically weak, with high valuation and bearish momentum. Swing traders may cautiously enter near support (~₹5,900–6,000) and exit near resistance (~₹6,250–6,350). Conservative traders should wait for stronger technical signals before entering.